Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 2215 Yukon Street VANCOUVER BC V5Y 0A1 |
Tel: | N/A |
Website: | https://www.abcellera.com |
IR: | See website |
Key People | ||
Carl L.G. Hansen Chairman of the Board, President, Chief Executive Officer, Co-Founder | Veronique Lecault Co-Founder, Chief Operating Officer, Director | Andrew Booth Chief Financial Officer |
Tryn T. Stimart Chief Compliance Officer, Corporate Secretary, Chief Legal Officer | Neil Aubuchon Chief Commercial Officer |
Business Overview |
AbCellera Biologics Inc. (AbCellera) is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera's full-stack, artificial intelligence (AI)-powered drug discovery platform integrates technologies from engineering, microfluidics, single-cell analysis, high-throughput genomics, machine learning, and hyper-scale data science. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, enabling them to tackle the toughest problems in drug development. |
Financial Overview |
For the six months ended 30 June 2022, AbCellera Biologics Inc revenues increased 57% to $362.5M. Net income increased 41% to $161.8M. Revenues reflect Royalty revenue increase of 77% to $340.2M, Research fees increase from $9.2M to $21.9M. Net income was partially offset by Royalty fees increase from $23.6M to $49.8M (expense), Research and development - Balancing val increase of 99% to $40.9M (expense). |
Employees: | 386 as of Dec 31, 2021 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $3,110M as of Jun 30, 2022 |
Annual revenue (TTM): | $507.34M as of Jun 30, 2022 |
EBITDA (TTM): | $286.60M as of Jun 30, 2022 |
Net annual income (TTM): | $200.36M as of Jun 30, 2022 |
Free cash flow (TTM): | $286.77M as of Jun 30, 2022 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 285,138,643 as of Aug 4, 2022 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |